



## Zevaskyn™ Gene Therapy Treatment Centers ETS Program Reference Guide

Emerging Therapy Solutions® (ETS) helps reinsurance and stop-loss payers, health plans, HMOs, and self-funded employers, along with third-party administrators and brokers, manage the risk associated with high-cost therapies for rare and complex conditions.

Programs listed here are manufacturer-approved treatment centers for which ETS has contracted rates in place or has access to rates through single case agreements for **Zevaskyn** (prademagene zamikeracel, pz-cel) which is approved to treat **recessive dystrophic epidermolysis bullosa (RDEB)**.

For assistance with your member referral or for more information, contact ETS at 877-445-4822 or by email at [clientservices@emergingtherapies.com](mailto:clientservices@emergingtherapies.com).

▼ Denotes facilities at which ETS has gene therapy rates in place.

| State        | City         | Program Listing                                      |
|--------------|--------------|------------------------------------------------------|
| California   | Palo Alto    | Lucile Packard Children's Hospital                   |
| Colorado     | Denver       | Children's Hospital Colorado                         |
| Illinois     | Chicago      | Ann & Robert H. Lurie Children's Hospital of Chicago |
| Ohio         | Cincinnati   | Cincinnati Children's Hospital Medical Center ▼      |
| Pennsylvania | Philadelphia | Children's Hospital of Philadelphia ▼                |